Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.1900
- TODAY'S CHANGE (%)-0.0100 (-0.3125%)
- Bid / Lots3.1000/ 5
- Ask / Lots3.2200/ 80
- Open / Previous Close3.2000 / 3.2000
- Day Range
- 52 Week Range
- Volume221,582
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 3740 | 3.17 |
| 09:34 ET | 495 | 3.193 |
| 09:38 ET | 2560 | 3.15 |
| 09:39 ET | 1200 | 3.16 |
| 09:41 ET | 100 | 3.17 |
| 09:45 ET | 257 | 3.18 |
| 09:48 ET | 100 | 3.18 |
| 09:52 ET | 17839 | 3.13 |
| 09:54 ET | 564 | 3.12 |
| 09:56 ET | 500 | 3.1109 |
| 09:57 ET | 286 | 3.11 |
| 10:01 ET | 294 | 3.12 |
| 10:06 ET | 1147 | 3.1002 |
| 10:10 ET | 100 | 3.11 |
| 10:12 ET | 3120 | 3.13 |
| 10:15 ET | 1000 | 3.1397 |
| 10:17 ET | 3800 | 3.1552 |
| 10:19 ET | 100 | 3.1543 |
| 10:26 ET | 100 | 3.155 |
| 10:30 ET | 200 | 3.15 |
| 10:32 ET | 379 | 3.154 |
| 10:33 ET | 1500 | 3.15 |
| 10:35 ET | 1000 | 3.1526 |
| 10:37 ET | 100 | 3.1549 |
| 10:39 ET | 2567 | 3.15 |
| 10:42 ET | 100 | 3.15 |
| 10:44 ET | 100 | 3.15 |
| 10:46 ET | 100 | 3.15 |
| 10:48 ET | 1048 | 3.16 |
| 10:50 ET | 458 | 3.16 |
| 10:55 ET | 1576 | 3.1899 |
| 11:15 ET | 100 | 3.18 |
| 11:20 ET | 100 | 3.18 |
| 11:22 ET | 100 | 3.18 |
| 11:24 ET | 1143 | 3.16 |
| 11:27 ET | 1107 | 3.1698 |
| 11:29 ET | 500 | 3.17 |
| 11:31 ET | 1573 | 3.1742 |
| 11:36 ET | 16795 | 3.13 |
| 11:38 ET | 4877 | 3.12 |
| 11:40 ET | 4835 | 3.1382 |
| 11:44 ET | 2474 | 3.14 |
| 11:51 ET | 300 | 3.15 |
| 11:54 ET | 500 | 3.15 |
| 12:00 ET | 100 | 3.16 |
| 12:02 ET | 300 | 3.15 |
| 12:05 ET | 200 | 3.14 |
| 12:07 ET | 1096 | 3.13 |
| 12:14 ET | 859 | 3.129 |
| 12:18 ET | 100 | 3.13 |
| 12:20 ET | 179 | 3.14 |
| 12:23 ET | 400 | 3.135 |
| 12:27 ET | 100 | 3.13 |
| 12:30 ET | 627 | 3.13 |
| 12:32 ET | 400 | 3.12 |
| 12:34 ET | 300 | 3.12 |
| 12:38 ET | 400 | 3.12 |
| 12:39 ET | 4640 | 3.12 |
| 12:41 ET | 795 | 3.12 |
| 12:43 ET | 287 | 3.12 |
| 12:45 ET | 598 | 3.12 |
| 12:48 ET | 849 | 3.1215 |
| 12:50 ET | 5600 | 3.12 |
| 12:52 ET | 1735 | 3.12 |
| 12:54 ET | 500 | 3.12 |
| 12:56 ET | 300 | 3.12 |
| 12:57 ET | 940 | 3.12 |
| 12:59 ET | 100 | 3.13 |
| 01:08 ET | 100 | 3.13 |
| 01:12 ET | 271 | 3.13 |
| 01:15 ET | 1400 | 3.12 |
| 01:19 ET | 3261 | 3.12 |
| 01:26 ET | 200 | 3.12 |
| 01:30 ET | 100 | 3.12 |
| 01:32 ET | 100 | 3.125 |
| 01:33 ET | 1649 | 3.13 |
| 01:35 ET | 200 | 3.1201 |
| 01:44 ET | 825 | 3.1289 |
| 01:46 ET | 111 | 3.1288 |
| 01:48 ET | 1187 | 3.14 |
| 01:50 ET | 709 | 3.13 |
| 02:08 ET | 100 | 3.13 |
| 02:18 ET | 608 | 3.134 |
| 02:20 ET | 892 | 3.1364 |
| 02:24 ET | 1400 | 3.1368 |
| 02:26 ET | 268 | 3.13 |
| 02:27 ET | 1855 | 3.13 |
| 02:29 ET | 805 | 3.137 |
| 02:33 ET | 1000 | 3.1366 |
| 02:36 ET | 100 | 3.13 |
| 02:40 ET | 160 | 3.13 |
| 02:42 ET | 1100 | 3.1387 |
| 02:44 ET | 1445 | 3.1258 |
| 02:45 ET | 716 | 3.14 |
| 02:47 ET | 200 | 3.1398 |
| 02:49 ET | 440 | 3.13 |
| 03:00 ET | 100 | 3.13 |
| 03:02 ET | 100 | 3.13 |
| 03:07 ET | 1723 | 3.14 |
| 03:09 ET | 1100 | 3.17 |
| 03:12 ET | 200 | 3.17 |
| 03:14 ET | 200 | 3.17 |
| 03:16 ET | 100 | 3.17 |
| 03:18 ET | 214 | 3.18 |
| 03:20 ET | 200 | 3.18 |
| 03:21 ET | 200 | 3.18 |
| 03:23 ET | 200 | 3.18 |
| 03:25 ET | 200 | 3.18 |
| 03:27 ET | 200 | 3.18 |
| 03:30 ET | 2200 | 3.17 |
| 03:34 ET | 300 | 3.18 |
| 03:36 ET | 300 | 3.18 |
| 03:38 ET | 200 | 3.18 |
| 03:39 ET | 200 | 3.18 |
| 03:41 ET | 300 | 3.18 |
| 03:43 ET | 300 | 3.18 |
| 03:45 ET | 2359 | 3.16 |
| 03:48 ET | 1100 | 3.17 |
| 03:50 ET | 100 | 3.18 |
| 03:52 ET | 8062 | 3.2 |
| 03:54 ET | 1142 | 3.2 |
| 03:56 ET | 883 | 3.195 |
| 03:57 ET | 1919 | 3.19 |
| 03:59 ET | 12405 | 3.19 |
Jun 25, 2024
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 189.5M | -6.3x | --- |
Rani Therapeutics Holdings Inc | 188.6M | -2.9x | --- |
Acrivon Therapeutics Inc | 218.3M | -2.5x | --- |
Trevi Therapeutics Inc | 181.7M | -7.6x | --- |
Candel Therapeutics Inc | 173.2M | -4.5x | --- |
Immutep Ltd | 288.3M | -7.4x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
